Can-Fite BioPharma Ltd. (CANF) has a negative trailing P/E of -794.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 1.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -0.13%, forward earnings yield 71.43%. PEG 0.06 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 37/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -95.6 | -8.60 | 170.50 | 3,888.41 | - |
| 2017 | -96.9 | 2.64 | 157.63 | 569.84 | - |
| 2018 | -74.6 | 7.09 | 162.58 | 128.32 | - |
| 2019 | -15.0 | 1.27 | 77.40 | 93.01 | - |
| 2020 | -28.1 | 0.39 | 66.72 | 531.13 | - |
| 2021 | -31.3 | 1.08 | 27.44 | 462.64 | - |
| 2022 | -32.6 | 0.56 | 74.19 | 409.58 | - |
| 2023 | -24.6 | 0.47 | 30.04 | 252.38 | - |
| 2024 | -30.0 | 0.75 | 43.50 | 350.86 | - |
| 2025 | -0.3 | 0.00 | 0.59 | 8.07 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-90.00 | $169.5K | $-6.9M | -4069.3% |
| 2017 | $-57.00 | $844.75K | $-4.97M | -588.2% |
| 2018 | $-51.00 | $3.82M | $-6.57M | -172% |
| 2019 | $-45.00 | $2.03M | $-13.05M | -642.3% |
| 2020 | $-12.69 | $763K | $-14.81M | -1940.5% |
| 2021 | $-8.25 | $853K | $-12.6M | -1476.6% |
| 2022 | $-3.75 | $810K | $-10.53M | -1300.4% |
| 2023 | $-1.80 | $743K | $-7.63M | -1027.5% |
| 2024 | $-1.08 | $674K | $-7.88M | -1169.1% |
| 2025 | $-12.03 | $408.21K | $-9.91M | -2426.7% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.83 | $-0.83 – $-0.83 | $20.6M | $20.6M – $20.6M | 1 |
| 2027 | $0.76 | $0.76 – $0.76 | $168.55M | $168.55M – $168.55M | 1 |
| 2028 | $1.55 | $1.55 – $1.55 | $306.12M | $306.12M – $306.12M | 1 |
| 2029 | $2.27 | $2.27 – $2.27 | $454.53M | $454.53M – $454.53M | 1 |
| 2030 | $2.82 | $2.82 – $2.82 | $614.43M | $614.43M – $614.43M | 1 |
